Business
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Data presentations explore effects on patient-centric efficacy measures of treatments for patients with depression, and excessive sleepiness associated with obstructive sleep apnea and narcolepsy NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations of data from its CNS portfolio at the 2023 U.S. Psych Congress, being held in Nashville, Tenn. from September 6-10. The presentations demonstrate the Company’s commitment to continued innovation to address unmet needs in difficult-to-treat CNS disorders. “Axsome’s presentations at Psych Congress highlight our commitment to advancing research of medicines that have the potential to improve the lives of patients with brain health conditions such as depression and sleep disorders,” said Cecilia Brain, MD, PhD, Vice President of Medical Affairs at Axsome. “These presentations explore the meaningful impact that our treatments could have for patients and underscore the unique pharmacology of our novel medicines which may be relevant to multiple clinical conditions.” The presentations will include eight posters with data and analyses which examine the effects of AUVELITY® (dextromethorphan-bupropion) on sleep quality and cognitive and physical functioning in patients with major depressive disorder (MDD), and the effects of SUNOSI® (solriamfetol) on cognition in patients with excessive daytime sleepiness (EDS) due to obstructive sleep apnea (OSA). Five of the eight posters are finalists under consideration for the Psych Congress Poster Awards. Key highlights include: Data examining durability of efficacy and tolerability with long-term (up to 12 months) treatment with AUVELITY in patients with MDD, including measures of depressive symptoms, anxiety, and cognitive and physical functioning. Data examining the effect of AUVELITY on depression-related disability, and patient-reported measures of insomnia in patients with MDD.Data examining treatment effect sizes of SUNOSI in patients with EDS associated with narcolepsy and OSA.Data examining the effects of SUNOSI on cognition in patients with EDS and OSA. All posters will be presented on September 8 and 9 from 1:30-3 p.m. Central Time in Exhibit Hall A a...